1. Introduction {#sec1}
===============

Chronic obstructive pulmonary disease (COPD) represents the fourth leading cause of death worldwide. There are over 40 million patients with COPD in China and over 1.28 million patients die of COPD per year \[[@B1]\]. The pathogenesis of COPD was affected by the multifactorial interactions of both environmental triggers and genetic susceptibility \[[@B2], [@B3]\]. In addition to other contributing factors including airway hyperresponsiveness, family history of asthma, chronic inflammation, and childhood respiratory infections \[[@B4], [@B5]\], environmental exposure like tobacco smoke absorption, which plays role in increasing goblet cells count, airway remodeling, and tissue destructing, is the most commonly recognized risk factor for COPD. However, Fletcher and Peto \[[@B6]\] suggested that only 10% to 15% smokers would develop to symptomatic COPD, revealing the susceptibility to tobacco smoke injury may be related to genetic variety among individuals. Up to now, a wide variety of researches had presented that single-nucleotide polymorphism (SNP) might have an effect on the quantity or activity of a specific protein, thus making individual and hereditary contribution to the COPD development \[[@B7]--[@B9]\].

Polycyclic aromatic hydrocarbons (PAHs), carcinogen mainly from cigarette smoking and air pollution, have been proved to be related to the development of COPD \[[@B10], [@B11]\]. One of PAH-metabolizing cytochrome P450 enzymes, CYP1A1, is a well-known aryl hydrocarbon hydroxylase, widely expressed in tissues including liver, lung, intestine, skin, lymphocytes, and macrophages \[[@B12]\]; many studies had investigated the carcinogenic role of these CYPs in related pulmonary disease including COPD \[[@B13]--[@B17]\]. Located in chromosome 15q22--24,*CYP1A1* gene contained lots of SNPs, among which MspI and Ile/Val polymorphisms were most widely studied.*CYP1A1* MspI polymorphism, which resulted in a T-C change in the 30-non-coding region of*CYP1A1*, might link to some other functional polymorphisms and thus has been reported to be associated with an increased enzyme activity \[[@B18]--[@B20]\]. Similarly, adenine to guanine transition at position 2455 in*CYP1A1* exon 7 also resulted in the substitution of Val for Ile in the enzyme active center \[[@B21]\]. Hence, these SNPs in*CYP1A1* gene might lead to an altered enzyme activity of detoxicating cigarette smoke products and thus be related to lung function and susceptibility of COPD \[[@B22], [@B23]\]. Moreover, lots of studies have reported that polymorphisms of*CYP1A1* gene could modify susceptibility to smoking-induced lung cancer \[[@B15], [@B24]\].

A few studies \[[@B25]--[@B34]\] have investigated the association between*CYP1A1* gene polymorphisms and COPD risk. However, their results were inconclusive partly because of limitation of population size, ethnicities, and other confounding factors. Thus we performed the first comprehensive meta-analysis including all eligible case-control studies to date, to assess the exact effect of*CYP1A1* MspI and Ile/Val polymorphisms on COPD risk.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

We performed a comprehensive search up to April 13, 2015, without language limitation in the following five electronic databases: PubMed, EMBASE, China National Knowledge Infrastructure (CNKI), Weipu, and WanFang databases. The following words were used as search terms: "COPD" or "chronic obstructive pulmonary disease" and "CYP1A1" or "cytochrome P4501A1" or "P4501A1" and "polymorphism" or "variant" or "mutation." Reference lists of relevant articles were also checked manually for potential eligible studies.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Studies were included if they met the following criteria: (1) case-control studies; (2) investigating the association between*CYP1A1* gene polymorphisms and susceptibility to COPD; (3) detailed genotype frequencies that were available to calculate odds ratios (OR) with a 95% confidence interval (CI). Studies were excluded if they were (1) conference abstracts, animal studies, cellular studies, or letters; (2) without available genotype frequencies; (3) duplication publications. When studies with overlapped case series were met, we included the studies with maximal subjects.

2.3. Data Extraction {#sec2.3}
--------------------

With a standard extraction table, two investigators (Lin Huang and Nan Chen) extracted the data independently. The following information was collected from each eligible study: first author\' name, year of publication, country, ethnicity of subjects, source of controls (hospital-based or population-based), matching criteria for controls, genotyping method, and genotype frequency distribution of cases and controls. These two investigators launched a final discussion to reach a consensus if any disagreement was met.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Person\'s Chi-square was conducted to assess the Hardy-Weinberg equilibrium of genotype frequencies in controls of each eligible study. *P* value less than 0.05 was regarded as significant disequilibrium. The data was excluded from the susceptibility analysis if significant disequilibrium existed. The strength of association between*CYP1A1* polymorphisms and susceptibility to COPD was evaluated by calculating the odds ratio (OR) with corresponding 95% confidence interval (CI) under the following five genetic models: dominant model, recessive model, homozygote comparison, heterozygote comparison, and allele model. To assess the significance of OR, we conducted the *Z* test and we regarded it as significant difference when *P* value less than 0.05 was detected. Moreover, *χ* ^2^ based *Q* and *I* ^2^ test were performed to evaluate the between-study heterogeneity and *P* \< 0.1 was defined as statistical significance. The random effect was used to calculate the OR if significant heterogeneity existed. Otherwise, the fixed-effects model was applied. Furthermore, we also conducted subgroup analyses stratified by ethnicity (Caucasian and Asian), source of controls (population-based and hospital-based), matching criteria (more than 2 items and less than 3 items), and sample size (larger than 300 and less than 300). Publication bias was assessed by asymmetry of funnel plots. In sensitivity analysis, we sequentially excluded each study on the software to evaluate the stability of the results. We conducted all the analyses by using software Review Manager 5.2.

3. Results {#sec3}
==========

3.1. Baseline Characteristics of Included Studies {#sec3.1}
-------------------------------------------------

Seventeen records were identified after searching these five databases mentioned above ([Figure 1](#fig1){ref-type="fig"}). After reviewing of title and abstract, 9 records were considered as potentially eligible and full texts were retrieved. After screening the full texts, we included seven studies which met our inclusion and exclusion criteria. Finally, a total of seven studies with 1050 cases and 1202 controls were included in our meta-analysis. When investigating association between Ile/Val polymorphism and COPD risk, Gaspar et al. \[[@B25]\] recruited controls apart from Hardy-Weinberg equilibrium and these data were excluded from susceptibility analysis. Thus there were six studies for MspI polymorphism and four studies for Ile/Val polymorphism. As for ethnicity, two studies were carried out among Caucasians and five studies were performed among Asians. Of eligible studies, three studies recruited controls from population and three studies recruited hospital-based controls. The detailed characteristics of eligible studies were presented in [Table 1](#tab1){ref-type="table"} and the genotype frequency distribution was shown in [Table 2](#tab2){ref-type="table"}.

3.2. Meta-Analysis Results {#sec3.2}
--------------------------

Overall, we observed a significant association between MspI polymorphisms and increased COPD risk (CC versus TC + TT: OR = 1.57, CI: 1.09--2.26, *P* = 0.02; CC versus TT: OR = 1.73, CI: 1.18--2.55, *P* = 0.005; [Figure 2](#fig2){ref-type="fig"}). In subgroup analysis stratified by ethnicity, a significant association between MspI polymorphisms and susceptibility to COPD was detected among Asians (CC versus TC + TT: OR = 1.70, CI: 1.06--2.71, *P* = 0.03; CC versus TT: OR = 1.84, CI: 1.11--3.06, *P* = 0.02; [Figure 3](#fig3){ref-type="fig"}). Furthermore, we also found a significant association in meta-analysis among studies with hospital-based controls (TC + CC versus TT: OR = 2.01, CI: 1.40--2.87, *P* \< 0.001), matching criteria (more than 2 items) (CC versus TT: OR = 2.01, CI: 1.06--3.81, *P* = 0.03), and sample size (more than 300) (CC versus TT: OR = 1.84, CI: 1.17--2.89, *P* = 0.009). The detailed results for subgroup analysis were shown in [Table 3](#tab3){ref-type="table"}.

Totally, a significant association between Ile/Val polymorphism and COPD risk was identified (GG versus AG + AA: OR = 2.75, CI: 1.29--5.84, *P* = 0.009; GG versus AA: OR = 3.23, CI: 1.50--6.93, *P* = 0.003; AG versus AA: OR = 1.39, CI: 1.01--1.90, *P* = 0.04; [Figure 4](#fig4){ref-type="fig"}). As for ethnicity, we did not detect any significant association between Ile/Val polymorphism and susceptibility to COPD among both Asian and Caucasian population. When stratified by source of controls, we observed a significant relationship with Ile/Val polymorphism and COPD risk among studies recruiting hospital-based controls (AG + GG versus AA: OR = 1.99, CI: 1.37--2.90, *P* \< 0.001; [Table 3](#tab3){ref-type="table"}).

3.3. Publication Bias and Sensitivity Analysis {#sec3.3}
----------------------------------------------

Publication bias was evaluated by funnel plots. The shape of the funnel plots seemed symmetric and it indicated no significant publication bias in our meta-analysis ([Figure 5](#fig5){ref-type="fig"}). Sensitivity analysis was also conducted by excluding individual studies sequentially. The results of meta-analysis did not change qualitatively by any single study, suggesting the stability of our results.

4. Discussion {#sec4}
=============

CYP1A1 is a well-known aryl hydrocarbon hydroxylase in CYP1 family; its function in xenobiotic biotransformation and antioxidant defense are crucial in protecting lungs from toxic agents \[[@B32], [@B33]\]. The variations in structure and function of CYP1A1 on account of MspI and Ile/Val polymorphisms might result in altered CYP1A1 enzyme activity and different rate of procarcinogens metabolism like PAHs \[[@B10]\], nitrosamines, and aromatic amines \[[@B19]\], thus generating individual\'s risk difference when exposed to environmental COPD inducers. Therefore, it is reasonable to speculate that impairment of lung function and pathogenesis of COPD may develop in individuals carrying the variant MspI and Ile/Val in CYP1A1. To eliminate existing shortages in published researches such as small simple size and other cofounding factors and to evaluate the exact relationship with CYP1A1 polymorphisms and COPD risk, we conducted the present meta-analysis of seven eligible case-control studies. Our result showed a significant association between both MspI and Ile/Val polymorphism and susceptibility to COPD, and stratified analyses showed that MspI polymorphism might also be related to increased COPD risk among Asians.

As one of our conclusions, significant association between MspI polymorphism and susceptibility to COPD was detected. Individuals with CC genotype of MspI polymorphism seemed to bear higher risk of COPD than that of TT genotype. In subgroup analysis, these results were also observed among Asians and a 1.84-fold higher risk was detected in individuals with CC genotype compared to TT genotype. The significant relationship was also identified in meta-analysis among studies with more matching criteria and larger sample size ([Table 3](#tab3){ref-type="table"}). These results indicated that the relationship between MspI polymorphism and risk of COPD in terms of Caucasian was further explored, and more well-designed studies with larger subjects were warranted. For Ile/Val polymorphism, a significant association between this polymorphism and COPD risk was also detected. Both AG and GG genotype might mean higher COPD risk than AA genotype. However, we did not find any association among both Asian and Caucasian population, which might be a result of relatively smaller sample size in subgroup analysis, which reflected the effective role of our meta-analysis and more studies were hoped in future; thus we could further examine the exact effect among ethnicities. Moreover, functional studies on the exact molecular mechanism were hoped to conduct in future. Although these results might be limited by quantity of included studies, we still believed a significant trend existed between*CYP1A1* polymorphisms and COPD risk and our meta-analysis figured out the direction of further studies. MspI and Ile/Val polymorphisms might be focused for more investigation as important genetic biomarkers, which might play a great role in development, diagnosis, treatment, and prognosis of COPD.

Moreover, effects of*CYP1A1* polymorphisms on COPD risk among both smokers and nonsmokers were worth evaluating. However, only few studies \[[@B30]\] assessed this issue and the data was insufficient to conduct meta-analysis. We expected more studies involved in this issue in future. Another important thing was that Cheng et al. \[[@B27]\] reported a significant association between MspI polymorphism and severity of COPD, and variant allele was higher among severe COPD patients. However, Putra et al. \[[@B29]\] indicated no relationship with*CYP1A1* polymorphisms and severity of COPD in their study. These data pieces could not be synthesized for different criteria of COPD severity used in their studies. Considering the results of our study, we hypothesized that variant allele of MspI polymorphism might contribute to more severe chronic inflammation and oxidative stress of lung and thus might be related to not only susceptibility to COPD but also further progression of COPD. Putra et al. \[[@B29]\] did not detect any association and it might be partly because of limitation of relatively smaller sample size. More studies were warranted to focus on this hypothesis and identify the finite conclusion.

There were some limitations that should be presented. First, only a few studies were published and included yet. More studies investigating these issues were warranted in future. Second, effect of Ile/Val polymorphism on COPD risk among other ethnicities was unavailable for lack of sufficient data. Further studies on Ile/Val polymorphism on COPD risk among different races were hoped. Third, our records were identified in specific standard databases in English and Chinese, some potential eligible studies in other languages might be left, and even though the possibility of omission was minimized, the publication bias might influence the results of this meta-analysis that cannot be absolutely excluded.

5. Conclusion {#sec5}
=============

Our meta-analysis demonstrated a significant association between both MspI and Ile/Val polymorphisms of*CYP1A1* gene and susceptibility to COPD. MspI polymorphism might also be related to increased COPD risk among Asians. Overall, in terms of the pathogenesis of COPD, genetic polymorphisms should be simultaneously considered to accomplish the comprehensive mechanism of varied environmental inducer sensitivity, which may be valued in individualized prevention and varied prognosis of COPD associated with environmental exposures. More well-designed studies with larger sample size were warranted.
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![Forest plot for the association between the*CAP1A1* MspI polymorphism and susceptibility to COPD under the homozygote comparison (CC versus TT). Significant association was observed between the MspI polymorphism and increased COPD risk.](BMRI2015-942958.002){#fig2}

![Forest plot of subgroup analysis for the association between the*CAP1A1* MpsI polymorphism and COPD risk among Asians (CC versus TT). We observed significant association between the MpsI polymorphism and COPD risk among Asians.](BMRI2015-942958.003){#fig3}

![Forest plot for the association between the*CAP1A1* Ile/Val polymorphism and susceptibility to COPD under the homozygote comparison (GG versus AA). Significant association was observed between the Ile/Val polymorphism and increased COPD risk.](BMRI2015-942958.004){#fig4}

![Begg\'s funnel plot on publication bias for included studies on the association of the*CAP1A1* MspI and Ile/Val polymorphisms with susceptibility to COPD. The symmetrical shape of the funnel plot indicated absence of publication bias.](BMRI2015-942958.005){#fig5}

###### 

Baseline characteristics of eligible case-control studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  First\     Year   Reference    Country   Ethnicity   Source of controls   Matching criteria\     Cases/controls   Quality control   Polymorphisms
  author                                                                    for controls                                              
  ---------- ------ ------------ --------- ----------- -------------------- ---------------------- ---------------- ----------------- ---------------
  Cheng      2009   \[[@B27]\]   China     Asian       PB                   Age                    184/212          NA                MspI,

  Gaspar     2004   \[[@B25]\]   Brazil    Caucasian   PB                   NA                     75/90            NA                MspI, Ile/Val

  Korytina   2008   \[[@B26]\]   Russia    Caucasian   PB                   Age, sex, ethnicity    319/418          NA                MspI, Ile/Val

  Putra      2013   \[[@B29]\]   Japan     Asian       HB/PB                Sex, ethnicity         48/172           Yes               MspI, Ile/Val

  Vibhuti    2010   \[[@B28]\]   India     Caucasian   HB                   Sex, ethnicity, area   210/136          NA                MspI, Ile/Val

  Wang       2008   \[[@B34]\]   China     Asian       HB                   Age, sex               115/94           NA                Ile/Val

  Yang       2014   \[[@B30]\]   China     Asian       HB                   Age, sex               101/80           NA                MspI
  ---------------------------------------------------------------------------------------------------------------------------------------------------

PB: population-based; HB: hospital-based; HB/PB: recruiting both population-based and hospital-based controls; NA: not available.

###### 

Genotype frequency distribution of *CYP1A1* polymorphisms.

  Polymorphisms         First author   Case      Control   HWE in controls   MAF in controls                                          
  --------------------- -------------- --------- --------- ----------------- ----------------- --------- ----- ----- ------ --------- ------
                                       *N* ^a^   TT        TC                CC                *N* ^a^   TT    TC    CC                
                                                                                                                                      
  MspI (rs4646903)      Cheng          184       76        78                30                212       85    107   20     2.76      0.35
  Gaspar                75             49        25        1                 90                64        21    5     2.97   0.17      
  Korytina              275            213       54        8                 387               277       102   8     0.15   0.15      
  Putra                 48             21        27        172               57                115       NA    NA                     
  Vibhuti               210            80        107       23                136               75        53    8     0.12   0.25      
  Yang                  101            28        49        24                80                35        31    14    2.24   0.37      
                                                                                                                                      
                                       *N* ^a^   AA        AG                GG                *N* ^a^   AA    AG    GG                
                                                                                                                                      
  Ile/Val (rs1048943)   Gaspar         75        59        16                0                 90        73    14    3      4.06^b^   0.11
  Korytina              317            292       25        0                 418               382       34    2     1.64   0.05      
  Putra                 48             28        20        172               93                79        NA    NA                     
  Vibhuti               210            141       46        23                136               109       24    3     1.38   0.11      
  Wang                  115            45        61        9                 94                53        37    4     0.62   0.24      

^a^Sample size of case group or control group.

^b^Gaspar recruited controls apart from Hardy-Weinberg equilibrium and thus these data were excluded from susceptibility analysis.

*N*: sample size in case or control group; NA: not available; HWE: Hardy-Weinberg equilibrium; MAF: minor allele frequency.

###### 

The results of evidence synthesis in this meta-analysis.

  Variables               Dominant model   Recessive model     Homozygote comparison   Heterozygote comparison   Additive model                                                                                                                                                        
  ----------------------- ---------------- ------------------- ----------------------- ------------------------- ---------------- -------------------- ------- ------ --- -------------------- ------- ------ --- ------------------- ------ -------- --- ------------------- -------- -------
  *MspI*                                                                                                                                                                                                                                                                                
  Total                   6                1.14 (0.77, 1.70)   0.51                    0.002                     5                1.57 (1.09, 2.26)    0.02    0.45   5   1.73 (1.18, 2.55)    0.005   0.34   5   1.22 (0.77, 1.94)   0.4    0.002    5   1.21 (0.91, 1.60)   0.2      0.02
  By ethnicity                                                                                                                                                                                                                                                                          
   Asian                  3                1.07 (0.59, 1.92)   0.83                    0.03                      2                1.70 (1.06, 2.71)    0.03    0.62   2   1.84 (1.11, 3.06)    0.02    0.65   2   1.22 (0.51, 2.89)   0.65   0.03     2   1.29 (0.94, 1.78)   0.06     0.2
   Caucasian              3                1.23 (0.63, 2.40)   0.55                    0.002                     3                1.39 (0.78, 2.48)    0.27    0.19   3   1.60 (0.89, 2.88)    0.12    0.12   3   1.24 (0.61, 2.51)   0.55   0.002    3   1.13 (0.69, 1.86)   0.62     0.008
  By source of controls                                                                                                                                                                                                                                                                 
   PB                     3                0.88 (0.69, 1.12)   0.3                     0.28                      3                1.48 (0.91, 2.41)    0.11    0.18   3   1.35 (0.81, 2.24)    0.25    0.27   3   0.82 (0.64, 1.07)   0.14   0.13     3   0.98 (0.80, 1.20)   0.85     0.31
   HB                     2                2.01 (1.40, 2.87)   0.0001                  0.97                      2                1.68 (0.97, 2.91)    0.06    0.61   2   2.40 (1.32, 4.36)    0.004   0.71   2   1.92 (1.32, 2.80)   0      0.92     2   1.65 (1.26, 2.14)   0.0002   0.82
  By matching criteria                                                                                                                                                                                                                                                                  
   More than 2 items      2                1.09 (0.83, 1.44)   0.52                    0.0005                    2                1.73 (0.92, 3.27)    0.09    0.62   2   2.01 (1.06, 3.81)    0.03    0.28   2   1.13 (0.42, 3.05)   0.81   0.0008   2   1.17 (0.57, 2.39)   0.67     0.002
   Less than 3 items      4                1.09 (0.83, 1.43)   0.55                    0.07                      3                1.49 (0.95, 2.33)    0.08    0.18   3   1.59 (0.98, 2.58)    0.06    0.21   3   1.29 (0.73, 2.30)   0.39   0.06     3   1.23 (0.98, 1.53)   0.07     0.38
  By sample size                                                                                                                                                                                                                                                                        
   \>300                  3                1.11 (0.62, 1.96)   0.73                    0.002                     3                1.80 (1.16, 2.79)    0.008   0.87   3   1.84 (1.17, 2.89)    0.009   0.52   3   1.01 (0.56, 1.83)   0.97   0.002    3   1.15 (0.77, 1.72)   0.49     0.008
   \<300                  3                1.20 (0.62, 2.33)   0.6                     0.04                      2                1.13 (0.58, 2.20)    0.72    0.11   2   0.96 (0.13, 7.25)    0.97    0.07   2   1.76 (1.09, 2.84)   0.02   0.63     2   1.37 (0.98, 1.92)   0.07     0.26
                                                                                                                                                                                                                                                                                       
  *Ile/Val*                                                                                                                                                                                                                                                                             
  Total                   4                1.34 (0.84, 2.13)   0.21                    0.04                      3                2.75 (1.29, 5.84)    0.009   0.15   3   3.23 (1.50, 6.93)    0.003   0.16   3   1.39 (1.01, 1.90)   0.04   0.21     3   1.50 (0.88, 2.55)   0.13     0.02
  By ethnicity                                                                                                                                                                                                                                                                          
   Asian                  2                1.32 (0.56, 3.11)   0.52                    0.04                                                                                                                                                                                             
   Caucasian              2                1.34 (0.63, 2.88)   0.45                    0.04                      2                1.67 (0.09, 30.45)   0.73    0.07   2   1.72 (0.09, 34.41)   0.72    0.06   2   1.19 (0.81, 1.74)   0.37   0.27     2   1.41 (0.55, 3.63)   0.48     0.005
  By source of controls                                                                                                                                                                                                                                                                 
   HB                     2                1.99 (1.37, 2.90)   0.0003                  0.96                      2                3.48 (1.50, 8.08)    0.004   0.23   2   4.24 (1.79, 10.04)   0.001   0.36   2   1.69 (1.13, 2.51)   0.01   0.5      2   1.94 (1.43, 2.64)   0.0001   0.33
  By matching criteria                                                                                                                                                                                                                                                                  
   More than 2 items      2                1.34 (0.63, 2.88)   0.45                    0.04                      2                1.67 (0.09, 30.45)   0.73    0.07   2   1.72 (0.09, 34.41)   0.72    0.06   2   1.19 (0.81, 1.74)   0.37   0.27     2   1.41 (0.55, 3.63)   0.48     0.005
   Less than 3 items      2                1.32 (0.56, 3.11)   0.52                    0.04                                                                                                                                                                                             
  By sample size                                                                                                                                                                                                                                                                        
   \>300                  2                1.34 (0.63, 2.88)   0.45                    0.04                      2                1.67 (0.09, 30.45)   0.73    0.07   2   1.72 (0.09, 34.41)   0.72    0.06   2   1.19 (0.81, 1.74)   0.37   0.27     2   1.41 (0.55, 3.63)   0.48     0.005
   \<300                  2                1.32 (0.56, 3.11)   0.52                    0.04                                                                                                                                                                                             

^a^Number of included studies in evidence synthesis.

*P*: *P* value of *Z* test to evaluate the significance of the ORs; *P* ~*h*~: *P* value of *Q* test for heterogeneity test.

[^1]: Academic Editor: Jill E. Larsen
